IDEXX Laboratories (IDXX) Set to Announce Quarterly Earnings on Thursday

IDEXX Laboratories (NASDAQ:IDXX) will announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $2.69 per share for the quarter. IDEXX Laboratories has set its FY 2024 guidance at 10.310-10.590 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. IDEXX Laboratories’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the company posted $2.67 EPS. On average, analysts expect IDEXX Laboratories to post $10 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IDEXX Laboratories Price Performance

IDXX opened at $457.90 on Thursday. The stock has a fifty day moving average of $486.11 and a 200-day moving average of $490.23. The firm has a market capitalization of $37.82 billion, a P/E ratio of 44.33, a PEG ratio of 4.14 and a beta of 1.33. IDEXX Laboratories has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.